

The Manager  
Company Announcements Office  
ASX Limited

## ST VINCENT'S HOSPITAL IN MELBOURNE TO BE GLOBAL FIRST APAS® TRIAL SITE

- *Australian-developed advanced pathology lab reading and interpretation to faster diagnose infections*
  - *Expected to be world-first site with this high speed and accurate automation*

**Adelaide, Australia, 21 June 2017:** Australian medical technology company LBT Innovations Limited (ASX: LBT) and joint venture company Clever Culture Systems AG (CCS) have received confirmation that St Vincent's Hospital in Melbourne will be the first laboratory in the world to trial an APAS® Independence instrument.

APAS® is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. The APAS® Independence improves the clinical efficiency of microbiology labs and enables faster diagnosis and reporting of infectious diseases. The US FDA-cleared device is based on LBT's Australian-developed intelligent imaging and interpretative software and based in a unit about the size of a large photo-copier.

LBT CEO and Managing Director Brent Barnes said, "This is a high calibre team working at St Vincent's Hospital and we are extremely happy to be working with them in what will be a global first. We have instruments currently undergoing advanced reliability and performance testing that will be finalised over the coming months ahead of the first placement at St Vincent's in September. We look forward to seeing the independent results of APAS® Independence used in a clinical laboratory setting for the first time as part of our global commercialisation milestones."

"This is a precursor to selling product in Australia and globally which we still expect to occur at the very end of 2017. Successfully commercialising APAS® Independence in Australia is a base to expand to larger global markets such as North America and Europe. These distribution plans will be more defined over coming months," said Barnes.

The important business milestones of product distribution, regulatory strategy and reference laboratory trials associated with the launch of APAS® Independence are clear for the global launch market of Australia:

- ✓ **Global Launch Market:** first launch market confirmed as Australia
- ✓ **Regulatory/TGA:** 28 March 2017: APAS® included on the Australian Register of Therapeutic Goods allowing the instrument to be sold and distributed in Australia
- ✓ **Distribution:** 14 June 2017: LBT appointed distributor for Australia and New Zealand to sell, market and service the APAS® technology
- ✓ **Reference Laboratory:** 21 June 2017: St Vincent's Hospital announced as first global trial site of APAS® Independence; to be placed in September 2017.

On 30 March Lisa Brenton, Senior Scientist Microbiology, St Vincent's Hospital presented on "The need for Automation in Microbiology" at an LBT briefing where the APAS® Independence was unveiled for the first time. This was an independent view of the need for automation in the microbiology market and not a comment on the APAS® Independence instrument.

Currently around the world microbiologists individually review AGAR plates of which up to 95% are negative. APAS Independence much more rapidly automatically reviews and sorts plates into neat stacks of negatives, positives and those to be reviewed. The APAS Independence reads and interprets 200 plates per hour and in independent clinical trials so far has demonstrated greater accuracy than microbiologists.

Following the St. Vincent's trial, the APAS® Independence will be trialled in additional microbiology centres of excellence to establish a global network of reference laboratories for the device.

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

### CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	Sarah Kemter Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 407 162 530 E: <a href="mailto:sarahk@monsoon.com.au">sarahk@monsoon.com.au</a>